Leflunomida Normon (Leflunomide)

Leflunomide blocks the enzyme dihydroorotate dehydrogenase, which is essential for pyrimidine synthesis. By limiting pyrimidine production, it suppresses the proliferation of activated lymphocytes, reducing the abnormal immune response that drives inflammation and joint destruction in autoimmune arthritis.

The dose of Leflunomida Normon is set by the prescribing physician based on the individual’s disease severity, laboratory results, and overall health status. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Leflunomida Normon is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of demonstrated fetal risk. It is also not recommended for breastfeeding mothers, as it may pass into breast milk and affect the infant.

To order Leflunomida Normon, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with conventional DMARDs such as methotrexate, Leflunomida Normon offers a different mechanism—pyrimidine synthesis inhibition—while providing similar efficacy in controlling disease activity. Unlike biologic agents, it is an oral medication, which may be preferred for patients seeking non‑injectable options, though safety monitoring differs.

Leflunomida Normon should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Leflunomida Normon is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the prescriber’s guidance regarding timing and any dietary considerations.

The most serious risks include severe liver injury, bone‑marrow suppression leading to anemia or low white‑blood‑cell counts, and pulmonary toxicity such as interstitial lung disease. Patients should undergo regular laboratory monitoring to detect these adverse events early.

Leflunomida Normon should not be used by pregnant women, individuals with severe liver disease, patients with uncontrolled hypertension, or those with known hypersensitivity to leflunomide or its excipients. It is also contraindicated in patients who are planning pregnancy without appropriate contraception.